官方社群在线客服官方频道防骗查询货币工具

Novartis Lifts FY24 Outlook After Q3 Beats Market; But Stock Down

2025年01月01日 02:15:45
news.like.tgnews.like.tgnews.like.tgnews.like.tg

LIKE.TG | 发现全球营销软件&服务汇聚顶尖互联网营销和AI营销产品,提供一站式出海营销解决方案。唯一官网:www.like.tg

(RTTNews) - Swiss drug major Novartis AG on Tuesday raised its core operating income and sales guidance for fiscal 2024 after reporting significantly higher profit in its third quarter, driven by sales growth in key drugs. The third-quarter core earnings and topline beat market estimates.

Meanwhile, the shares were losing around 3 percent in the Swiss trading as well as in early morning trading on the NYSE.

Vas Narasimhan, CEO of Novartis, said, "Novartis delivered another quarter of strong operational performance in Q3, with sales up 10 percent and core operating income up 20 percent. All key growth drivers contributed to the momentum. With the momentum in our business and pipeline, we were able to once again upgrade our full-year guidance and remain highly confident in our mid-term outlook."

For the full year, Novartis now expects its core operating income growth in high teens against prior outlook for a growth from mid to high teens.

Annual sales are now projected to grow in low double-digits, compared with previous expectation for a high single to low double-digit growth.

In its third quarter, net earnings of the drug maker stood at $3.185 billion, up from last year's $1.763 billion. Earnings per share surged to $1.58 from $0.85 in the prior year.

Excluding prior year's discontinued operations, net income grew 111 percent from last year's $1.513 billion, and earnings per share surged 116 percent from $0.73 in the prior year.

Core net income on a continuing operations was $4.13 billion, compared to $3.59 billion last year. Core earnings per share were $2.06, compared to $1.74 a year ago.

Analysts on average expected the company to report earnings of $1.96 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

Operating income grew 106 percent from last year to $3.63 billion, and core operating income went up 17 percent to $5.15 billion.

Core operating income margin was 40.1 percent, 340 basis points higher than last year, mainly driven by higher net sales.

Net sales improved 9 percent to $12.823 billion from prior year's $11.782 billion. At constant currency rates, net sales went up 10 percent. The Street was looking for sales of $12.76 billion for the quarter.

Entresto brand generated sales of $1.865 billion, up 26 percent at CC from last year. Sales of Cosentyx brand rose by 27 percent to $1.693 billion.

In Switzerland, Novartis shares were trading at 97.17 francs, down 2.65 percent.

On the NYSE, the shares were at $111.68, down 3.42 percent.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

LIKE.TG汇集全球营销软件&服务,助力出海企业营销增长。提供最新的“私域营销获客”“跨境电商”“全球客服”“金融支持”“web3”等一手资讯新闻。

点击【联系客服】 🎁 免费领 1G 住宅代理IP/proxy, 即刻体验 WhatsApp、LINE、Telegram、Twitter、ZALO、Instagram、signal等获客系统,社媒账号购买 & 粉丝引流自助服务或关注【LIKE.TG出海指南频道】【LIKE.TG生态链-全球资源互联社区】连接全球出海营销资源。

本文由LIKE.TG编辑部转载自互联网并编辑,如有侵权影响,请联系官方客服,将为您妥善处理。

This article is republished from public internet and edited by the LIKE.TG editorial department. If there is any infringement, please contact our official customer service for proper handling.


Server deployment全球论坛人工智能论坛全球峰会发展论坛战略论坛开放论坛程序员论坛互联网峰会科技峰会
加入like.tg生态圈,即可获利、结识全球供应商、拥抱全球软件生态圈加入like.tg平台,即可获利、结识全球供应商、拥抱全球营销软件生态圈加入like.tg生态资源圈,即可获利、结识全球供应商、拥抱全球软件生态圈
加入like.tg生态圈,即可获利、结识全球供应商、拥抱全球软件生态圈加入like.tg平台,即可获利、结识全球供应商、拥抱全球营销软件生态圈加入like.tg生态资源圈,即可获利、结识全球供应商、拥抱全球软件生态圈